Cohan, Stanley L. http://orcid.org/0000-0002-9568-346X
Benedict, Ralph H. B. http://orcid.org/0000-0002-2080-3631
Cree, Bruce A. C. http://orcid.org/0000-0001-7689-2533
DeLuca, John http://orcid.org/0000-0003-3745-4156
Hua, Le H. http://orcid.org/0000-0002-0535-3978
Chun, Jerold http://orcid.org/0000-0003-3964-0921
Funding for this research was provided by:
Novartis Pharmaceuticals Corporation
Article History
Accepted: 12 May 2022
First Online: 20 June 2022
Declarations
:
: Medical writing support for this article and open access publication was funded by Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
: <i>Stanley L. Cohan</i> has received speaking fees from Biogen, Bristol Myers Squibb, Novartis, Roche Genentech, and Sanofi Genzyme; and serves on advisory boards for or as a consultant to AbbVie, Biogen, Bristol Myers Squibb/Celgene, Novartis, Pear Therapeutics, and Sanofi Genzyme. Institutional research support (the Providence Brain and Spine Institute) has been received from AbbVie, Adamas, Biogen, MedDay, Novartis, Roche Genentech, Sage Bionetworks, and Sanofi Genzyme. <i>Ralph H.B. Benedict</i> has received fees and speaking or consulting fees from Biogen, Bristol Meyers Squibb, EMD Serono, Genentech, Genzyme, Immunic Therapeutics, Latin American Committee for Treatment and Research in Multiple Sclerosis, Merck, Novartis, Roche, and Sanofi; research support from Biogen, Bristol Meyers Squibb, Genentech, Genzyme, Novartis, National Institutes of Health, National Multiple Sclerosis Society, and Verasci; and royalties from Psychological Assessment Resources. <i>Bruce A.C. Cree</i> has received personal compensation for consulting from Alexion, Atara Biotherapeutics, Autobahn Therapeutics, Avotres, Biogen, EMD Serono, Neuron23, Novartis, Sanofi, TG Therapeutics, and Therini Bio; and research support from Genentech. <i>John DeLuca</i> has received speaking fees from Biogen and Sanofi Genzyme; has served on advisory boards for or as a consultant to Biogen, Celgene, F. Hoffmann-La Roche, MedRhythms, the National Multiple Sclerosis Society, and Novartis; and has received research support from Biogen, Celgene, the Consortium of Multiple Sclerosis Centers, EMD Serono, Genentech, the International Progressive Alliance, the National Multiple Sclerosis Society, and the National Multiple Sclerosis Society of Canada. <i>Le H. Hua</i> has received personal fees for speaking, consulting, and advisory board activities from Alexion, Bristol Myers Squibb, EMD Serono, Genentech, Genzyme, Greenwich, Horizon, Novartis, and TG Therapeutics; and research support from Biogen paid to her institution. <i>Jerold Chun</i> has received consulting fees or research support from Abbott, AbbVie, Amira Pharmaceuticals, Arena Pharmaceuticals, Biogen Idec, BioLineRx, Blade Therapeutics, Brainstorm Cell Therapeutics, Celgene, GlaxoSmithKline, Inception Sciences, Johnson & Johnson, Merck, Mitsubishi Tanabe Pharma, Novartis, Ono Pharmaceutical, Pfizer, SKAI Ventures, Taisho Pharmaceutical Co., and Travecta Therapeutics.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: All authors discussed and agreed on the concept for the article. APR and SG performed the literature research and data analysis and drafted the manuscript. All authors critically reviewed the data and each manuscript draft, have read and approved the final submitted manuscript, and agree to be accountable for the work.